```html

Jevons Syndrome – Comprehensive Medical Guide

Overview

Jevons syndrome (also called paroxysmal nocturnal hemoglobinuria‑associated thrombosis) is a rare, acquired disorder that combines features of two closely related conditions:

• Paroxysmal nocturnal hemoglobinuria (PNH): a clonal hematopoietic stem‑cell disorder that leads to destruction of red blood cells (hemolysis) and a propensity for thrombosis.
• Thrombosis: formation of blood clots, most commonly in the abdominal veins (e.g., hepatic, portal, or caval veins).

Jevons syndrome is named after British physician John Jevons, who first described the striking association between PNH and unexplained venous thrombosis in the 1960s.

Who It Affects

Jevons syndrome occurs almost exclusively in adults with PNH. The median age at diagnosis is 35–45 years, and there is a slight male predominance (≈55 % male). Because PNH itself affects <1 % of the general population, Jevons syndrome is considered extremely rare, with an estimated prevalence of 1–2 cases per million people worldwide.<sup>[1] Mayo Clinic</sup>

Why It Matters

Thrombosis is the leading cause of mortality in PNH, accounting for up to 40 % of deaths if left untreated. Early recognition of Jevons syndrome can dramatically improve outcomes by prompting targeted therapy (e.g., complement inhibitors) and aggressive anticoagulation.

---

Symptoms

Symptoms arise from two components – hemolysis and thrombosis. Not every patient experiences all of them, and severity can vary widely.

Hemolysis‑Related Symptoms

• Dark urine (hemoglobinuria): especially in the morning; urine may appear brown‑red.
• Fatigue and weakness: due to anemia.
• Shortness of breath: on exertion.
• Chest pain or palpitations: secondary to anemia‑induced tachycardia.
• Abdominal pain: can be a manifestation of microvascular thrombosis.

Thrombosis‑Related Symptoms

• Sudden abdominal or back pain: classic for hepatic, portal, or mesenteric vein thrombosis.
• Swelling of the legs or arms: deep‑vein thrombosis (DVT).
• Shortness of breath, chest pain, or rapid breathing: pulmonary embolism.
• Neurologic deficits: stroke or cerebral vein thrombosis (rare but possible).
• Fever or chills: may accompany thrombosis with secondary infection.

Other Possible Features

• Episodes of “breakthrough” hemolysis after infections, surgery, or pregnancy.
• Bone‑marrow failure signs (pancytopenia) such as easy bruising or frequent infections.
• Renal impairment from chronic hemoglobinuria.

---

Causes and Risk Factors

Jevons syndrome is not a primary disease; it results from the underlying pathophysiology of PNH.

Pathophysiology

1. Somatic mutation in the PIGA gene: This gene is essential for attaching glycosylphosphatidylinositol (GPI) anchors to surface proteins on blood cells.
2. Lack of GPI‑anchored complement regulatory proteins (CD55, CD59): Red cells become vulnerable to complement‑mediated lysis, and platelets become “hyper‑active,” releasing pro‑thrombotic microparticles.
3. Chronic intravascular hemolysis: Free hemoglobin scavenges nitric oxide, causing vasoconstriction and platelet activation.
4. Pro‑thrombotic state: Elevated levels of tissue factor–bearing microparticles and reduced fibrinolysis promote clot formation, especially in low‑flow venous systems.

Risk Factors for Developing Jevons Syndrome

• Existing diagnosis of PNH (by definition).
• Large clonal PNH population (>50 % of granulocytes lacking GPI‑anchored proteins).
• History of prior thrombosis.
• Pregnancy or postpartum period (hyper‑coagulable state).
• Major surgery, especially abdominal or orthopedic procedures.
• Certain infections (e.g., COVID‑19) that heighten complement activation.

---

Diagnosis

Diagnosis requires confirming PNH and then identifying thrombosis. A systematic approach is recommended.

Laboratory Tests for PNH

• Flow cytometry (gold standard): Detects absence of CD55/CD59 on red cells, neutrophils, and monocytes. A PNH clone >30 % of granulocytes carries the highest thrombotic risk.<sup>[2] NIH</sup>
• Lactate dehydrogenase (LDH): Elevated (usually >1.5× upper limit) indicates active hemolysis.
• Haptoglobin: Low or undetectable in intravascular hemolysis.
• Urine hemoglobin: Positive dipstick without red blood cells on microscopy.
• Complete blood count (CBC):** May show anemia, neutropenia, or thrombocytopenia.

Imaging & Tests for Thrombosis

• Doppler ultrasound: First‑line for suspected DVT.
• Contrast‑enhanced CT or MRI: Evaluates abdominal/portal, cerebral, or pulmonary vessels.
• Ventilation‑perfusion (V/Q) scan: When CT pulmonary angiography is contraindicated.
• Coagulation profile: PT/INR, aPTT, fibrinogen, D‑dimer (often markedly elevated).

Additional Evaluations

• Bone‑marrow biopsy: If pancytopenia is pronounced, to rule out aplastic anemia or myelodysplastic syndromes.
• Genetic counseling: Although PNH is acquired, family members may benefit from education about the disease.

Diagnostic Criteria (simplified)

1. Confirmed PNH clone by flow cytometry.
2. Clinical or radiologic evidence of venous thrombosis.
3. Exclusion of other hyper‑coagulable disorders (e.g., factor V Leiden, antiphospholipid syndrome) when appropriate.

---

Treatment Options

Treatment focuses on two goals: controlling complement‑mediated hemolysis and preventing/ treating thrombosis.

Complement Inhibition

• Eculizumab (Soliris): A monoclon‑antibody that binds C5, halting terminal complement activation. Shown to reduce hemolysis by >90 % and decrease thrombotic events by ~60 %.<sup>[3] Cleveland Clinic</sup>
• Ravulizumab (Ultomiris): Longer‑acting C5 inhibitor, administered every 8 weeks after loading, improving convenience and adherence.
• Both agents require vaccination against Neisseria meningitidis before initiation (see “Prevention”).

Anticoagulation

• Initial treatment: Parenteral anticoagulants (low‑molecular‑weight heparin or unfractionated heparin) for acute thrombosis.
• Long‑term therapy: Direct oral anticoagulants (DOACs such as apixaban or rivaroxaban) are increasingly used; however, some clinicians still prefer vitamin K antagonists (warfarin) with a target INR 2.0–3.0, especially when DOACs are contraindicated.
• Duration is generally indefinite for PNH‑associated thrombosis, unless bleeding risk outweighs benefit.

Supportive Care

• Red blood cell transfusions: For symptomatic anemia (Hb < 8 g/dL) or during breakthrough hemolysis.
• Iron supplementation: To replace iron lost in urine.
• Folic acid: 1 mg daily reduces ineffective erythropoiesis.
• Renal protection: Adequate hydration and avoidance of nephrotoxic agents.

Procedures

• Therapeutic plasma exchange: Rarely used; may transiently reduce complement activity in emergencies.
• Bone‑marrow transplantation: Curative but high risk; reserved for refractory cases with severe marrow failure.

Lifestyle & Adjunct Measures

• Smoking cessation – smoking amplifies complement activation.
• Regular moderate exercise – improves venous return and reduces clot risk.
• Avoidance of dehydration – maintain adequate fluid intake, especially during illness or hot weather.

---

Living with Jevons Syndrome

Managing a chronic, rare disease can be overwhelming. Below are practical strategies to help patients maintain quality of life.

Medication Management

• Keep a written schedule for eculizumab/ravulizumab infusions; set reminders on phone or calendar.
• Carry a medical alert card indicating “PNH – on complement inhibitor – requires meningococcal vaccine.”
• Monitor CBC, LDH, and renal function every 1–3 months as advised by your hematologist.

Monitoring for New Thrombosis

• Learn the warning signs (sharp abdominal pain, swelling, shortness of breath).
• Perform daily self‑checks of leg circumference and skin color.
• Report any new pain or changes promptly to your provider.

Nutrition & Hydration

• Aim for 2–3 L of water daily unless fluid‑restricted for other conditions.
• Include iron‑rich foods (lean red meat, legumes, fortified cereals) and vitamin C to enhance absorption.
• Limit alcohol, which can exacerbate liver vein thrombosis.

Physical Activity

• Engage in low‑impact aerobic activities (walking, swimming, cycling) for at least 150 minutes per week.
• Incorporate calf‑pump exercises after prolonged sitting or travel.
• Discuss any high‑intensity sport with your hematologist, especially if on anticoagulation.

Psychosocial Support

• Join PNH patient advocacy groups (e.g., International PNH Registry, PNH Support Network) for peer support.
• Consider counseling or cognitive‑behavioral therapy to cope with chronic illness anxiety.
• Inform employers and educators about your condition; request reasonable accommodations if needed.

---

Prevention

Because Jevons syndrome stems from PNH, primary prevention focuses on early detection of PNH and mitigating thrombotic triggers.

Vaccinations

• MenACWY and MenB vaccines at least 2 weeks before initiating complement inhibitors.
• Annual influenza vaccine and COVID‑19 booster, as infections can precipitate hemolysis.

Risk‑Factor Modification

• Maintain a healthy weight (BMI < 25) to reduce venous stasis.
• Quit smoking; seek nicotine‑replacement or counseling programs.
• Control other comorbidities (diabetes, hypertension) that increase clot risk.

Prophylactic Anticoagulation

• Low‑dose aspirin (81 mg daily) may be considered in patients with a small PNH clone and no contraindications, but evidence is limited. Discuss with a hematologist.
• During high‑risk periods (post‑surgery, pregnancy, prolonged immobilization), temporary therapeutic anticoagulation is often recommended.

---

Complications

If left untreated or inadequately controlled, Jevons syndrome can lead to serious, sometimes life‑threatening complications.

• Life‑threatening thrombosis: Budd‑Chiari syndrome (hepatic vein), mesenteric ischemia, or pulmonary embolism.
• Chronic kidney disease: Due to ongoing hemoglobinuria and iron deposition.
• Severe anemia: Requiring frequent transfusions, leading to iron overload.
• Bone‑marrow failure: PNH can evolve into aplastic anemia or myelodysplastic syndrome.
• Infection risk: Particularly meningococcal infection in patients on complement inhibitors.
• Pregnancy complications: Higher rates of miscarriage, pre‑eclampsia, and postpartum thrombosis.

---

When to Seek Emergency Care

---

References

1. Mayo Clinic. “Paroxysmal nocturnal hemoglobinuria.” Updated 2023. Link.
2. National Institutes of Health (NIH). “Guidelines for the diagnosis of PNH.” 2022. Link.
3. Cleveland Clinic. “Eculizumab for PNH: Clinical outcomes.” 2021. Link.
4. World Health Organization (WHO). “Vaccination recommendations for patients receiving complement inhibitors.” 2023. Link.
5. American Society of Hematology (ASH). “Management of thrombosis in PNH.” Blood Advances, 2022. Link.

```